Europska Unija - hrvatski - EMA (European Medicines Agency)

correvio - vernakalant hidroklorid - fibrilacija atrija - srčana terapija - brza transformacija nedavnog početka фибрилляции vrlo značajan u синусовый ritam i za odrasle:za non-kirurških bolesnika: fibrilacija atrija .

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dalbavancin hydrochloride - soft tissue infections; skin diseases, bacterial - antibakterijski lijekovi za sistemsku primjenu, - liječenje akutnih bakterijskih infekcija kože i strukture kože (absssi) u odraslih osoba.

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).

Europska Unija - hrvatski - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastična sredstva - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. za daljnje informacije o stanju čovjeka epidermalnog faktora rasta receptora 2 (her2), molimo pogledajte odjeljak 5. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. dodatne informacije o statusu her2 potražite u odjeljku 5. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bayer d.o.o., radnička cesta 80, zagreb, hrvatska - tekući ekstrakt iz svježe biljke gorke ognjice (1:1,5-2,5), ekstrakcijsko otapalo: etanol 50 % v/v tekući ekstrakt kamiličinog cvijeta (1:2-4), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt kimovog ploda (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt matičnjakovog lista (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt lista paprene metvice (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt sladićevog korijena (1:2,5 -3,5), ekstrakcijsko otapalo: etanol 30 % v/v - oralne kapi, tekućina - urbroj: 1 ml sadrži: 0,15 ml tekućeg ekstrakta gorke ognjice (iberis amara l., platna tota recens) (1 : 1,5 – 2,5), ekstrakcijsko otapalo etanol 50 % v/v 0,30 ml tekućeg ekstrakta cvijeta kamilice (matricaria recutica l., flos) (1 : 2 – 4), ekstrakcijsko otapalo etanol 30 % v/v 0,20 ml tekućeg ekstrakta ploda kima (carum carvi l., fructus) (1 : 2,5 – 3,5), ekstrakcijsko otapalo etanol 30 % v/v 0,15 ml tekućeg ekstrakta listova matičnjaka (melissa officinalis l., folium) (1 : 2,5 – 3,5), ekstrakcijsko otapalo etanol 30 % v/v 0,10 ml tekućeg ekstrakta listova paprene metvice (mentha piperita l., folium) (1 : 2,5 – 3,5), ekstrakcijsko otapalo etanol 30 % (v/v) 0,10 ml tekućeg ekstrakta korijena sladića (glycyrrhiza glabra l. i/ili g. ionflata bat. i/ili g. uralensis fisch, radix) (1 : 2,5 – 3,5), ekstrakcijsko otapalo etanol 30 % v/v

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bayer d.o.o., radnička cesta 80, zagreb, hrvatska - tekući ekstrakt kamiličinog cvijeta (1:2-4), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt sikavičinog ploda (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt matičnjakovog lista (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt lista paprene metvice (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt iz svježe biljke gorke ognjice (1:1,5-2,5), ekstrakcijsko otapalo: etanol 50 % v/v tekući ekstrakt anđelikinog korijena (1:2,5 -3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt kimovog ploda (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt zeleni običnog rosopasa (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v tekući ekstrakt sladićevog korijena (1:2,5 -3,5), ekstrakcijsko otapalo: etanol 30 % v/v - oralne kapi, tekućina - 100 ml - urbroj: 100 ml oralnih kapi, otopine sadrži: 15 ml tekućeg ekstrakta iz iberis amara l., totum (gorka ognjica) (1:1,5-2,5), ekstrakcijsko otapalo: etanol 50 % v/v; 10 ml tekućeg ekstrakta iz angelica archangelica l. (archangelica officinalis haffm.), radix (anđelikin korijen) (1:2,5 -3,5), ekstrakcijsko otapalo: etanol 30% v/v; 20 ml tekućeg ekstrakta iz matricaria recutita l.(chamomilla recutita (l.) rauschert), flos (kamiličin cvijet) (1:2-4), ekstrakcijsko otapalo: etanol 30% v/v; 10 ml tekućeg ekstrakta iz carum carvi l., fructus (kimov plod) (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v; 10 ml tekućeg ekstrakta iz silybum marianum l.gaertner, fructus (sikavičin plod) (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v; 10 ml tekućeg ekstrakta iz melissa officinalis l., folium (matičnjakov list)(1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v; 5 ml tekućeg ekstrakta iz mentha x piperita l., folium (list paprene metvice) (1: 2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v; 10 ml tekućeg ekstrakta iz chelidonium majus l., herba (zelen rosopasa običnog) (1:2,5-3,5), ekstrakcijsko otapalo: etanol 30% v/v; 10 ml tekućeg ekstrakta iz glycyrrhiza glabra l., radix (sladićev korijen) (1:2,5 -3,5), ekstrakcijsko otapalo: etanol 30 % v/v

Europska Unija - hrvatski - EMA (European Medicines Agency)

novo nordisk a/s - inzulin degludec - Šećerna bolest - lijekovi koji se koriste u dijabetesu - liječenje dijabetes melitusa kod odraslih.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - danmavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - ivabradinklorid - filmom obložena tableta - 5 mg - urbroj: jedna filmom obložena tableta sadrži 5 mg ivabradina (što odgovara 5,390 mg ivabradinklorida)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - ivabradinklorid - filmom obložena tableta - 7,5 mg - urbroj: jedna filmom obložena tableta sadrži 7,5 mg ivabradina (što odgovara 8,085 mg ivabradinklorida)